Yaz: Comprehensive Evidence-Based Product Monograph

Product Description Yaz (drospirenone/ethinyl estradiol) represents a significant evolution in combined oral contraceptive (COC) technology, distinguished primarily by its unique progestin component—drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic properties. Unlike older progestins derived from testosterone or progesterone, drospirenone’s pharmacological profile more closely mimics natural progesterone, offering distinct therapeutic advantages beyond simple ovulation suppression. The formulation contains 3 mg drospirenone combined with 0.02 mg ethinyl estradiol, administered in a 24/4 regimen—24 active tablets followed by 4 inert placebo tablets.